Erasca (ERAS) Stock Price, News & Analysis

Company Overview

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Key Stats

• Today's Range: $1.17 to $1.25
• 50-Day Range: $1.06 to $1.58
• 52-Week Range: $1.01 to $3.45
• Volume: 616,963 shs
• Average Volume: 1.80 million shs
• Market Capitalization: $342.78 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.57
• Consensus Rating: Buy

Erasca Stock Analysis - MarketRank™

Erasca scored higher than 72% of companies evaluated by MarketBeat, and ranked 267th out of 917 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Buy

Consensus Rating

Erasca has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Erasca has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Erasca are expected to grow in the coming year, from ($0.73) to ($0.61) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Erasca is -1.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Erasca is -1.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Erasca has a P/B Ratio of 0.58. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

13.33% of the float of Erasca has been sold short.

Short Interest Ratio / Days to Cover

Erasca has a short interest ratio ("days to cover") of 13.4, which indicates bearish sentiment.

Change versus previous month

Short interest in Erasca has recently decreased by 7.19%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Erasca does not currently pay a dividend.

Dividend Growth

Erasca does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

13.33% of the float of Erasca has been sold short.

Short Interest Ratio / Days to Cover

Erasca has a short interest ratio ("days to cover") of 13.4, which indicates bearish sentiment.

Change versus previous month

Short interest in Erasca has recently decreased by 7.19%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 1.00

News Sentiment

Erasca has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Erasca this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for ERAS on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Erasca insiders have not sold or bought any company stock.

Percentage Held by Insiders

14.40% of the stock of Erasca is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

67.78% of the stock of Erasca is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ERAS Stock Analysis - Frequently Asked Questions

How have ERAS shares performed this year?

Erasca's stock was trading at $2.51 on January 1st, 2025. Since then, ERAS shares have decreased by 51.8% and is now trading at $1.21.
View the best growth stocks for 2025 here.

How were Erasca's earnings last quarter?

Erasca, Inc. (NASDAQ:ERAS) posted its quarterly earnings data on Tuesday, May, 13th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $0.01.

When did Erasca IPO?

Erasca (ERAS) raised $262 million in an IPO on Thursday, July 15th 2021. The company issued 17,500,000 shares at a price of $14.00-$16.00 per share.

Who are Erasca's major shareholders?

Top institutional investors of Erasca include Frazier Life Sciences Management L.P. (7.97%), T. Rowe Price Investment Management Inc. (6.10%), Paradigm Biocapital Advisors LP (3.81%) and Siren L.L.C. (3.09%). Insiders that own company stock include Jonathan E Lim, Bihua Chen, Alexander W Casdin and Valerie Denise Harding Start.
View institutional ownership trends.

How do I buy shares of Erasca?

Shares of ERAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Erasca own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Erasca investors own include Waste Connections (WCN), The RMR Group (RMR), AUO (AUOTY), American Water Works (AWK), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 5/23/2025
• Next Earnings (Estimated): 8/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ERAS
• CIK: 1761918
• Web: www.erasca.com
• Phone: 858-465-6511
• Fax: N/A
• Employees: 120
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $4.57
• High Stock Price Target: $6.00
• Low Stock Price Target: $3.00
• Potential Upside/Downside: +277.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 7 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.62)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-125,040,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -42.26%
• Return on Assets: -34.97%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 11.00
• Quick Ratio: 11.00

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.10 per share
• Price / Book: 0.58

Miscellaneous

• Outstanding Shares: 283,287,000
• Free Float: 221,941,000
• Market Cap: $342.78 million
• Optionable: Optionable
• Beta: 1.12